# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

# CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 11, 2008

## Greatbatch, Inc.

(Exact name of registrant as specified in its charter)

<u>Delaware</u> (State or other jurisdiction of incorporation) 1-16137 (Commission File Number) 16-1531026 (IRS Employer Identification No.)

9645 Wehrle Drive, Clarence, New York 14031 (Address of principal executive offices and Zip Code)

Registrant's telephone number, including area code: (716)-759-6901

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of

#### **Section 8 – Other Events**

#### Item 8.01 Other Events.

On February 11, 2008, Greatbatch issued a press release, a copy of which is attached hereto as Exhibit 99.1, disclosing that Precimed, S.A., an indirect wholly-owned subsidiary of Greatbatch, Inc., completed its previously announced acquisition of the DePuy Orthopaedics' Chaumont, France manufacturing facility.

#### Item 9.01 Financial Statements and Exhibits.

(c) Exhibits.

**Exhibit No.** Title of Exhibit

99.1 Press Release of Greatbatch, Inc. dated February 11, 2008

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

#### GREATBATCH, INC.

Date: February 11, 2008 By: /s/ Thomas J. Mazza

Thomas J. Mazza

Senior Vice President and Chief Financial Officer

#### Greatbatch Announces Acquisition Of DePuy Orthopaedics ' Chaumont, France Manufacturing Facility

CLARENCE, N.Y.--(BUSINESS WIRE)--Greatbatch, Inc. (NYSE: GB) announced today that its subsidiary Precimed, S.A. ("Precimed") has successfully completed the previously announced acquisition of DePuy's Chaumont, France manufacturing facility. The Chaumont facility will continue to produce primary hip stems and shoulder implants for DePuy for the foreseeable future.

This transaction, including a new 4-year supply agreement with DePuy, enhances Greatbatch's and Precimed's strategic relationship with one of the largest orthopedic companies in the world. The addition of this facility will align Precimed closer to its orthopedic OEM customers and further extends its offerings to a full range of orthopedic implants notably for the hip, shoulder and knee segments. The Chaumont facility has approximately 200 highly skilled employees with large-scale manufacturing expertise including machining of metals and plastics, engraving and laser etching, surface treatments, in house HA coatings capabilities and a Class 100,000 clean room with the ability to deliver a sterile packaged, fully labeled implant.

The acquisition of the DePuy facility was structured as an asset purchase. The purchase price was funded with cash on hand and availability under Greatbatch's revolving credit agreement.

#### About Greatbatch, Inc.

Greatbatch, Inc. (NYSE: GB) is a leading developer and manufacturer of critical components used in medical devices for the cardiac rhythm management, neurostimulation, vascular, orthopedic and interventional radiology markets. Additionally, Electrochem Commercial Power, a subsidiary of Greatbatch, is a world leader in the design and manufacture of electrochemical cells, battery packs and wireless sensors for demanding applications such as oil and gas exploration, pipeline inspection, military, asset tracking, oceanography, external medical and seismic surveying. Additional information about the Company is available at www.greatbatch.com.

CONTACT:
Greatbatch, Inc.
Anthony Borowicz, 716-759-5809
Treasurer and Director, Investor Relations tborowicz@greatbatch.com